Leora Horn, MD, on NSCLC: Ensartinib vs Crizotinib in ALK–Positive Disease

August 26, 2020 By The ASCO Post Staff

Leora Horn, MD, of Vanderbilt University, discusses phase III results from the eXalt3 trial, which suggest that ensartinib, a novel, next-generation ALK inhibitor, is superior to crizotinib in terms of progression-free survival as well as efficacy in central nervous system metastases for patients with ALK-positive non–small cell lung cancer (Abstract 2).

Related Content